Investigational drug · Phase 3
bemdaneprocel
Also called: MSK-DA01, BRT-DA01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinsons Disease (PD).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "bemdaneprocel"
First trial start
2025
Jun 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "bemdaneprocel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinsons Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "bemdaneprocel" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseasePivotal-lookingRecruiting
BlueRock TherapeuticsIndustry
NCT06944522 · 102 participants (planned) · Start Jun 17, 2025 · Primary completion Oct 2028
Drug: bemdaneprocel · For: Parkinsons Disease (PD)
Sites: Scottsdale, Arizona; Sun City, Arizona; Little Rock, Arkansas · 43 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease.
Tabar V, Sarva H, Lozano AM, et al. · Nature 2025
- Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01.
Piao J, Zabierowski S, Dubose BN, et al. · Cell Stem Cell 2021
Also in development for Parkinsons Disease (PD)
- NE3107bezisterimPhase 22 trials
BioVie Inc. · Long COVID, Parkinsons Disease (PD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.